Scientific database and research platform CiteAb announced on Monday the launch of its CiteAb Explore Platform, comprising the Reagent Search Engine and new Image Search Engine.
Built on over a decade of AI-driven data collection combined with expert human curation, CiteAb's database contains 16 million research tools and their use in 40 million publications, covering antibodies, proteins, models, kits and more. As of 2026, instrument data is also included. This data underpins the Explore Platform, which helps researchers identify fit-for-purpose reagents, faster.
The new Image Search tool is designed to enable researchers to rapidly investigate peer-reviewed scientific images. Developed with input from the scientific community, it provides easy access to 850,000 cropped experimental images -- covering 610,000 proteins, 5,000 diseases, and 160,000 cell lines -- linked directly to publications and the reagents used.
Together, the research tools in CiteAb Explore are intended to help researchers cut time spent navigating fragmented data sources, reduce R&D waste, and achieve more reproducible results.
The CiteAb Explore platform is freely accessible to academics, with a paid subscription model for commercial users.
Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit
AsymBio builds integrated platforms across biopharmaceutical development lifecycle
Evogene expands Google Cloud collaboration to integrate AI agents into ChemPass AI
Cumulus Neuroscience enters Japanese market with Shionogi collaboration
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
CiteAb launches new scientific image search tool and improved reagent search engine
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
BioArctic and Eisai secure Priority Review in China for subcutaneous Leqembi
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Delonix Bioworks gets IND clearance for DX-104 in China
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288